| Scleroderma Medical News by Date |
| |
| June 2009 |
| Distinct Autoimmune Syndromes in Morphea A Review of 245 Adult and Pediatric Cases. High prevalences of concomitant and familial autoimmune disease, systemic manifestations, and antinuclear antibody positivity in the generalized and possibly mixed subtypes suggest that these are systemic autoimmune syndromes and not skin-only phenomena. This has implications for the management and treatment of patients with morphea. Justin J. Leitenberger, BS. Archives of Dermatology. Vol. 145 No. 5, May 2009. (Also see: Morphea and Genetics) |
| Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. Non-invasive assessment of pulmonary circulation during physical exercise and/or hypoxia enables screening for pulmonary vascular dysfunction in scleroderma. Reichenberger F. (PubMed) Respir Med. 2009 Jun 2. (Also see: Pulmonary Hypertension) |
| Diagnosis of Raynaud's Phenomenon (RP) by 99mTc-Hydroxymethylene Diphosphonate Digital (Tc-HDP) Blood Flow Scintigraphy After One-hand Chilling. 99mTc-HDP digital blood flow scintigraphy after one-hand chilling is a noninvasive, accurate, and quantitative method to evaluate RP. Seong-Ryul Kwan. JRheum. June 16 2009. (Also see: Raynaud’s Diagnosis) |
| Experience of Mycophenolate Mofetil (MMF) in 10 Patients With Autoimmune-Related Interstitial Lung Disease Demonstrates Promising Effects. MMF is safe, well tolerated, and allows reduction or discontinuation of prednisone without worsening of symptoms or objective progression of disease. L. A, Saketkoo, MD American Journal of the Medical Sciences. 337(5):329-335, May 2009. (Also see: Pulmonary Fibrosis and Cellcept) |
| Immunological Reconstitution after Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Systemic Sclerosis: Relationship Between Clinical Benefits and Intensity of Immunosuppression. Our results suggest that immunosuppression intensity, sufficient to induce transient suppression of thymic function, is attributable to the feasible clinical response in patients with SSc treated with HSCT. Toshiyuki Bohgaki, The Journal of Rheumatology. Vol. 36 No. 6 1240-1248. May 15, 2009. (Also see: Stem Cell Transplants) |
| Improved endothelial function after endothelin (ET(A)) receptor blockade in patients with systemic sclerosis (SSc). The results of this study suggest novel vasculoprotective effects of ET(A) receptor antagonism and support further exploration of strategies that target the endothelin 1 pathway in SSc. C. Cardillo. (PubMed) Arthritis Rheum. June 2009 (Also see: Endothelin and Vascular Involvement) |
| Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine (DISTOL-1). This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Principal Investigator: James Seibold, MD. Started May 2009. ClinicalTrials.gov. (Also see: Scleroderma Treatments and Clinical Trials and Digital Ulcers) |
| Raynaud’s Phenomenon and Plasma Endothelin (ET-1): Correlations with Capillaroscopic Patterns in Systemic Sclerosis (SSc). Highest ET-1 plasma levels were detected in the more advanced stage of the SSc microangiopathy, namely the late nailfold videocapillaroscopy pattern, characterized by capillary loss and increased tissue fibrosis; this might support the involvement of ET-1 in the progression of the microvascular/fibrotic SSc damage. Alberto Sulli. Journal of Rheumatology. June 2009, 36 (6). (Also see: Raynaud's and Causes of Scleroderma) |
| Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis (SSc). Antiphospholipid (aPL) antibodies are often detected in systemic autoimmune diseases. Positivity for IgG aCL and IgG a-B2GPI in patients with SSc without secondary antiphospholipid syndrome seems to be connected with decrease of glomerular filtration. Ewa Wielosz Clinical Rheumatology 13 May 2009. (Also see: Antibodies and Kidney (Renal) Involvement) |
| Limited Scleroderma (CREST Syndrome). For some people, the problems caused by limited scleroderma are minor. For others, limited scleroderma can be life altering and even fatal. (New page at the Mayo Clinic.) Mayo Clinic. 06/02/09. (Also see: Limited Scleroderma) |
| Magnetic Resonance Imaging (MRI) of the Hand in Systemic Sclerosis. Our study illustrates the usefulness of MRI in the accurate diagnosis and characterization of SSc-associated arthropathy. Andrea H.L. Low Journal of Rheumatology 30 March 2009. (Also see: Skeletal Involvement) |
| Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. These parameters might suggest that autoantibody to both hnRNP antigens might become a non-specific but useful marker for joint involvement in SSc patients and identify SSc patients prone to develop joint damage. Sergio Generini. Rheumatology Advanced Access. May 29, 2009. (Also see: Antibodies and Skeletal Involvement) |
| Sexual Dysfunction among Women with Connective Tissue Disease. The Female Sexual Function Index (FSFI), consisting of six domains was used to assess the multidimensional nature of female sexual dysfunction among women with scleroderma. Our results show a high prevalence of sexual dysfunction among female scleroderma patients compared to a healthy control population. Erica Anderson (IngentaConnect) Current Rheumatology Reviews, Vol 5, No 2, May 2009 , pp. 126-132(7). (Also see: Female Sexual Dysfunction) |
| Low-dose Ultraviolet-A1 (UVA1) phototherapy for proximal and acral scleroderma in systemic sclerosis. This study would suggest that UVA1 phototherapy is effective for scleroderma affecting proximal and acral sites in patients with systemic sclerosis. Rose RF. (PubMed) Photodermatol Photoimmunol Photomed. 2009 Jun;25(3):153-5. (Also see: Skin Fibrosis and Sclerodactyly) |
| Bayer Schering Pharma Presents Positive Results Of Phase II Study With Riociguat. Results from the multi-center, open-label, uncontrolled phase II trial, showed that riociguat significantly improved exercise capacity from baseline values in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Medical News Today. 05/21/09. (Also see: Clinical Trials and PAH) |
| Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Riociguat is currently being investigated in phase III clinical trials for the oral treatment of PH after promising results in phase II trials. J Mittendorf. National Institutes of Health PubMed. May 2009. (Also see: Clinical Trials and PAH) |
Hello, I am